172 related articles for article (PubMed ID: 8556529)
61. Biological correlates of capsular (quellung) reactions of Cryptococcus neoformans.
MacGill TC; MacGill RS; Casadevall A; Kozel TR
J Immunol; 2000 May; 164(9):4835-42. PubMed ID: 10779792
[TBL] [Abstract][Full Text] [Related]
62. Protective murine monoclonal antibodies to Cryptococcus neoformans.
Mukherjee J; Scharff MD; Casadevall A
Infect Immun; 1992 Nov; 60(11):4534-41. PubMed ID: 1398966
[TBL] [Abstract][Full Text] [Related]
63. Serotyping of Cryptococcus neoformans by using a monoclonal antibody specific for capsular polysaccharide.
Dromer F; Gueho E; Ronin O; Dupont B
J Clin Microbiol; 1993 Feb; 31(2):359-63. PubMed ID: 8432823
[TBL] [Abstract][Full Text] [Related]
64. Anticryptococcal type D antibodies raised in rabbits.
Bhattacharjee AK; Bennett JE; Bundle DR; Glaudemans CP
Mol Immunol; 1983 Apr; 20(4):351-9. PubMed ID: 6191205
[TBL] [Abstract][Full Text] [Related]
65. Antibody to Cryptococcus neoformans capsular glucuronoxylomannan promotes expression of interleukin-12Rbeta2 subunit on human T cells in vitro through effects mediated by antigen-presenting cells.
Vecchiarelli A; Pietrella D; Bistoni F; Kozel TR; Casadevall A
Immunology; 2002 Jun; 106(2):267-72. PubMed ID: 12047756
[TBL] [Abstract][Full Text] [Related]
66. Antibodies to keyhole limpet hemocyanin cross-react with an epitope on the polysaccharide capsule of Cryptococcus neoformans and other carbohydrates: implications for vaccine development.
May RJ; Beenhouwer DO; Scharff MD
J Immunol; 2003 Nov; 171(9):4905-12. PubMed ID: 14568972
[TBL] [Abstract][Full Text] [Related]
67. Monoclonal antibody 13F1 produces annular immunofluorescence patterns on Cryptococcus neoformans serotype AD isolates.
Cleare W; Brandt ME; Casadevall A
J Clin Microbiol; 1999 Sep; 37(9):3080. PubMed ID: 10475750
[No Abstract] [Full Text] [Related]
68. Determination of antigen binding specificities of Cryptococcus neoformans factor sera by enzyme-linked immunosorbent assay.
Belay T; Cherniak R
Infect Immun; 1995 May; 63(5):1810-9. PubMed ID: 7537249
[TBL] [Abstract][Full Text] [Related]
69. Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy.
Nussbaum G; Cleare W; Casadevall A; Scharff MD; Valadon P
J Exp Med; 1997 Feb; 185(4):685-94. PubMed ID: 9034147
[TBL] [Abstract][Full Text] [Related]
70. Immunoglobulin M efficacy against Cryptococcus neoformans: mechanism, dose dependence, and prozone-like effects in passive protection experiments.
Taborda CP; Casadevall A
J Immunol; 2001 Feb; 166(3):2100-7. PubMed ID: 11160261
[TBL] [Abstract][Full Text] [Related]
71. The cellular responses induced by the capsular polysaccharide of Cryptococcus neoformans differ depending on the presence or absence of specific protective antibodies.
Vecchiarelli A
Curr Mol Med; 2005 Jun; 5(4):413-20. PubMed ID: 15977997
[TBL] [Abstract][Full Text] [Related]
72. An anti-Cryptococcus neoformans monoclonal antibody directed against galactoxylomannan.
van de Moer A; Salhi SL; Cherniak R; Pau B; Garrigues ML; Bastide JM
Res Immunol; 1990 Jan; 141(1):33-42. PubMed ID: 2189167
[TBL] [Abstract][Full Text] [Related]
73. A novel monoclonal antibody recognizing beta(1-3) glucans in intact cells of Candida and Cryptococcus.
Kondori N; Edebo L; Mattsby-Baltzer I
APMIS; 2008 Oct; 116(10):867-76. PubMed ID: 19132980
[TBL] [Abstract][Full Text] [Related]
74. Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection.
Mukherjee J; Pirofski LA; Scharff MD; Casadevall A
Proc Natl Acad Sci U S A; 1993 Apr; 90(8):3636-40. PubMed ID: 8475112
[TBL] [Abstract][Full Text] [Related]
75. Molecular identification of Cryptococcus neoformans serotypes.
Enache-Angoulvant A; Chandenier J; Symoens F; Lacube P; Bolognini J; Douchet C; Poirot JL; Hennequin C
J Clin Microbiol; 2007 Apr; 45(4):1261-5. PubMed ID: 17287323
[TBL] [Abstract][Full Text] [Related]
76. The capsule of cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages.
Kozel TR; Gotschlich EC
J Immunol; 1982 Oct; 129(4):1675-80. PubMed ID: 7050244
[TBL] [Abstract][Full Text] [Related]
77. Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody.
Goldman DL; Lee SC; Casadevall A
Infect Immun; 1995 Sep; 63(9):3448-53. PubMed ID: 7642276
[TBL] [Abstract][Full Text] [Related]
78. [Monoclonal antibodies recognizing the capsular polysaccharide of Cryptococcus neoformans].
Rodríguez Sánchez H; Pupo Antúnez M; Ilnait MT; Otero A; Martínez Machín G
Rev Cubana Med Trop; 2005; 57(2):162-4. PubMed ID: 17966590
[TBL] [Abstract][Full Text] [Related]
79. The heat shock protein (Hsp) 70 of Cryptococcus neoformans is associated with the fungal cell surface and influences the interaction between yeast and host cells.
Silveira CP; Piffer AC; Kmetzsch L; Fonseca FL; Soares DA; Staats CC; Rodrigues ML; Schrank A; Vainstein MH
Fungal Genet Biol; 2013 Nov; 60():53-63. PubMed ID: 23954835
[TBL] [Abstract][Full Text] [Related]
80. Isotype can affect the fine specificity of an antibody for a polysaccharide antigen.
McLean GR; Torres M; Elguezabal N; Nakouzi A; Casadevall A
J Immunol; 2002 Aug; 169(3):1379-86. PubMed ID: 12133962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
